This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cynamon, M. H.
Right arrow Articles by Sklaney, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cynamon, M. H.
Right arrow Articles by Sklaney, M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2003, p. 2442-2444, Vol. 47, No. 8
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.8.2442-2444.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Gatifloxacin and Ethionamide as the Foundation for Therapy of Tuberculosis

Michael H. Cynamon* and Mary Sklaney

Department of Medicine, Veterans Affairs Medical Center, Syracuse, New York

Received 6 December 2002/ Returned for modification 9 January 2003/ Accepted 8 May 2003

The use of gatifloxacin (GAT) in combination with ethionamide (ETA) with or without pyrazinamide (PZA) for a 12-week treatment period followed by an 8-week observation period was evaluated in a model of tuberculosis in mice. Mice treated with GAT at 300 mg/kg of body weight in combination with ETA (25 mg/kg) for 5 days per week had sterile lungs, whereas mice treated with GAT (100 mg/kg) and ETA (25 mg/kg) had about 10 CFU/lung; however, there was regrowth of the organisms in both groups at the end of the observation period. When PZA (450 mg/kg 5 days per week) was added to the high-dose GAT-ETA regimen, no viable mycobacteria were present after the 8-week observation period. GAT in combination with ETA and PZA has great promise for the treatment of tuberculosis.

* Corresponding author. Mailing address: VAMC, 800 Irving Ave., Syracuse, NY 13210. Phone: (315) 425-4884. Fax: (315) 425-4871. E-mail: Michael.Cynamon{at}Med.VA.Gov.

Antimicrobial Agents and Chemotherapy, August 2003, p. 2442-2444, Vol. 47, No. 8
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.8.2442-2444.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Louw, G. E., Warren, R. M., Gey van Pittius, N. C., McEvoy, C. R. E., Van Helden, P. D., Victor, T. C. (2009). A Balancing Act: Efflux/Influx in Mycobacterial Drug Resistance. Antimicrob. Agents Chemother. 53: 3181-3189 [Full Text]  
  • van den Boogaard, J., Kibiki, G. S., Kisanga, E. R., Boeree, M. J., Aarnoutse, R. E. (2009). New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development. Antimicrob. Agents Chemother. 53: 849-862 [Full Text]  
  • Shiraishi, Y., Katsuragi, N., Kita, H., Toishi, M., Onda, T. (2008). Experience with pulmonary resection for extensively drug-resistant tuberculosis. ICVTS 7: 1075-1078 [Abstract] [Full Text]  
  • Cynamon, M., Sklaney, M. R., Shoen, C. (2007). Gatifloxacin in combination with rifampicin in a murine tuberculosis model. J Antimicrob Chemother 60: 429-432 [Abstract] [Full Text]  
  • Lounis, N., Veziris, N., Chauffour, A., Truffot-Pernot, C., Andries, K., Jarlier, V. (2006). Combinations of R207910 with Drugs Used To Treat Multidrug-Resistant Tuberculosis Have the Potential To Shorten Treatment Duration. Antimicrob. Agents Chemother. 50: 3543-3547 [Abstract] [Full Text]  
  • Paramasivan, C. N., Sulochana, S., Kubendiran, G., Venkatesan, P., Mitchison, D. A. (2005). Bactericidal Action of Gatifloxacin, Rifampin, and Isoniazid on Logarithmic- and Stationary-Phase Cultures of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 49: 627-631 [Abstract] [Full Text]  
  • Shoen, C. M., DeStefano, M. S., Sklaney, M. R., Monica, B. J., Slee, A. M., Cynamon, M. H. (2004). Short-course treatment regimen to identify potential antituberculous agents in a murine model of tuberculosis. J Antimicrob Chemother 53: 641-645 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»